SNDX
HealthcareSyndax Pharmaceuticals, Inc. · Biotechnology · $2B
What is Syndax Pharmaceuticals, Inc.?
Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing targeted therapies for cancer and serious blood disorders. Headquartered in Waltham, Massachusetts, the company is advancing a pipeline built around novel mechanisms in oncology.
Syndax generates no product revenue yet — it invests in clinical research to bring new cancer treatments to patients. Its pipeline targets acute myeloid leukemia and chronic graft versus host disease through distinct biological mechanisms. The company funds operations through partnerships, licensing agreements, and capital markets, with collaborations including the National Cancer Institute and Eastern Cooperative Oncology Group.
Syndax Pharmaceuticals was incorporated in 2005 and is headquartered in Waltham, Massachusetts.
- SNDX-5613 (revumenib) — a Menin inhibitor in trials for MLL-rearranged and NPM1-mutant acute myeloid leukemia
- Axatilimab (SNDX-6352) — a monoclonal antibody targeting the CSF-1 receptor for chronic graft versus host disease
- Entinostat — an epigenetic therapy candidate in oncology development
- Collaborative research agreements with the National Cancer Institute and ECOG
Is SNDX a Good Stock to Buy?
UQS Score rates SNDX as Below Average overall, reflecting the realities of a pre-revenue clinical-stage company.
The Growth pillar stands out as Strong — a meaningful signal that the pipeline carries genuine forward momentum. Clinical-stage biotechs often show this pattern when late-stage catalysts are approaching.
Both the Quality and Moat pillars are rated Weak, consistent with a company that has no commercial products yet and limited durable competitive advantages. Valuation is rated Elevated, suggesting the market has already priced in significant pipeline optimism.
See the full pillar breakdown and underlying financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does SNDX pay dividends?
No — Syndax Pharmaceuticals, Inc. does not currently pay a dividend.
Syndax does not pay a dividend, which is typical for clinical-stage biopharmaceutical companies. All available capital is directed toward funding clinical trials and advancing the pipeline toward potential regulatory approval. Income-focused investors should look elsewhere; SNDX is a pure growth and pipeline story.
When does SNDX report earnings?
Syndax Pharmaceuticals reports financial results on a quarterly cadence, standard for US-listed companies.
As a pre-revenue company, quarterly results center on cash runway, operating expenses, and clinical trial progress rather than sales or profitability. Pipeline milestones and partnership updates tend to move the stock more than earnings beats or misses.
For the most recent quarter's results and management commentary, visit Syndax Pharmaceuticals' investor relations page directly.
SNDX Price History
+27.0% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
SNDX Long-term Outlook
The Strong Growth pillar suggests the market sees meaningful upside potential tied to pipeline readouts and potential regulatory approvals. However, the Elevated Valuation pillar indicates that much of this optimism may already be reflected in the share price. The Neutral Risk pillar points to a company that is neither unusually fragile nor unusually well-insulated — binary clinical outcomes remain the dominant variable.
Growth drivers
- Potential regulatory approval and commercialization of lead pipeline candidates in AML and cGVHD
- Expanding clinical collaborations with institutions like the National Cancer Institute
- Licensing and partnership agreements that could provide non-dilutive capital
Key risks
- Clinical trial failure or regulatory setbacks could significantly impair the investment thesis
- Elevated valuation leaves limited margin of safety if pipeline timelines slip
- Ongoing cash burn typical of pre-revenue biotech companies requires continued access to capital markets
SNDX vs Peers
Syndax competes in the clinical-stage specialty biotech space alongside other companies developing treatments for rare and serious conditions.
Ocular Therapeutix focuses on ophthalmic drug delivery rather than oncology, representing a different therapeutic area within the clinical-stage biotech universe.
Aurinia has advanced into commercial-stage operations with an approved therapy for lupus nephritis, giving it a revenue base that Syndax has not yet achieved.
Immunome pursues oncology and infectious disease targets using antibody discovery platforms, overlapping with Syndax in the cancer treatment space at a similar development stage.
Frequently Asked Questions
What does Syndax Pharmaceuticals do?
Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company developing cancer therapies. Its lead programs target acute myeloid leukemia through a Menin inhibitor and chronic graft versus host disease through a CSF-1 receptor-blocking antibody. The company has not yet commercialized a product.
Does SNDX pay dividends?
No, Syndax does not pay a dividend. Like most clinical-stage biotechs, the company reinvests all capital into research and clinical development. Investors in SNDX are betting on pipeline success rather than income generation.
When does SNDX report earnings?
Syndax reports on a quarterly cadence typical of US-listed companies. Because it is pre-revenue, results focus on operating expenses and cash position rather than sales. Check Syndax's investor relations page for the latest scheduled reporting dates.
Is SNDX a good stock to buy?
UQS Score rates SNDX as Below Average overall. The Growth pillar is Strong, reflecting pipeline potential, but Quality and Moat are both Weak and Valuation is Elevated. Whether that profile suits an investor depends on their risk tolerance and time horizon. The full pillar breakdown is available to Pro members.
Is SNDX overvalued?
The UQS Valuation pillar for SNDX is rated Elevated, suggesting the current price reflects a high degree of pipeline optimism. For a pre-revenue company, valuation is inherently speculative and tied to clinical outcomes rather than current earnings.
How does SNDX compare to its competitors?
Among clinical-stage peers, SNDX is differentiated by its focus on leukemia and graft versus host disease. Competitors like Aurinia Pharmaceuticals have already reached commercial stage, while others like Immunome share a similar development-stage profile. The UQS platform scores each peer independently for direct comparison.
What is SNDX's market cap bracket?
Syndax Pharmaceuticals is classified as a mid-cap company. This places it above the smallest clinical-stage biotechs in terms of market value, though it remains well below large established pharmaceutical companies.
Who founded Syndax Pharmaceuticals?
Syndax Pharmaceuticals was incorporated in 2005. Founding and leadership history is publicly available through the company's official filings and investor relations materials for those seeking detailed background.
Is SNDX a long-term quality investment?
From a long-term quality standpoint, SNDX's UQS profile shows a Weak Quality pillar and Weak Moat — both factors that matter for sustained value creation. The Strong Growth pillar offers a counterbalance, but long-term quality indicators currently lag behind growth potential. Pro members can view the complete analysis.
What is the main competitive advantage of Syndax Pharmaceuticals?
Syndax's differentiation lies in its focus on mechanistically distinct targets — the Menin-MLL interaction in leukemia and the CSF-1 receptor in graft versus host disease. These are specialized niches with limited approved therapies, giving the pipeline potential first-mover relevance if trials succeed.
Unlock Full SNDX Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS pillar scores across Quality, Growth, Moat, Risk, and Valuation
- ✓Access underlying financial metrics driving each pillar rating
- ✓Compare SNDX side-by-side with clinical-stage peers on a standardized scoring framework
- ✓Track pillar changes over time as pipeline milestones evolve
- ✓Get the complete analyst-style view available only to Pro members
Pro Analysis
SNDX — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 12, 2026 | 32.0 | 12.9 | 25.0 | 68.3 | 58.8 | 0.0 | +0.1 |
| Apr 22, 2026 | 31.9 | 12.9 | 25.0 | 68.2 | 58.8 | 0.0 | -3.5 |
| Apr 2, 2026 | 35.4 | 12.9 | 25.0 | 85.2 | 58.8 | 0.0 | — |
SNDX — Pillar Breakdown
Quality
— 12.9/100 (25%)Syndax Pharmaceuticals, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 68.3/100 (20%)Syndax Pharmaceuticals, Inc. demonstrates healthy growth trends across revenue and earnings.
Revenue trajectory over the last twelve months.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 58.8/100 (15%)Syndax Pharmaceuticals, Inc. maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)Syndax Pharmaceuticals, Inc. appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 25/100 (25%)Syndax Pharmaceuticals, Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for SNDX.
Score Composition
Financial Data
More Stock Analysis
How is the SNDX UQS Score Calculated?
The UQS (Unified Quality Score) for Syndax Pharmaceuticals, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Syndax Pharmaceuticals, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Syndax Pharmaceuticals, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.